Millennium Management
TVRD

Millennium Management’s Tvardi Therapeutics TVRD Stock Holding History

Millennium Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,247
Closed -$2.91M – 3932
2017
Q2 		$2.91M Buy
+5,247
New +$3.33M 0.01% 1848

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management's TVRD Position: Q2 2025 in Review

Millennium Management sold out of Tvardi Therapeutics (TVRD) in Q2 2025, closing a stake of 5,807 shares — an estimated $88.3K sold.

Millennium Management first reported a position in TVRD in Q4 2014 and held it in 33 quarters. The position peaked at $13.2M in Q4 2015. 56 funds tracked by Wall St. Rank hold TVRD as of Q2 2025.

  • Millennium Management reported no remaining Tvardi Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Millennium Management sold 5,807 Tvardi Therapeutics shares in Q2 2025, an estimated $88.3K.
  • Millennium Management first reported a position in Tvardi Therapeutics in Q4 2014 and held it in 33 quarters.
  • Millennium Management's Tvardi Therapeutics position peaked at $13.2M in Q4 2015.
  • 56 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2025.

Based on Millennium Management's 13F filing for Q2 2025, filed 14 Aug 2025.